EUVIMEDSkopri EUVIMED
StudienprotokollOpen access

Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data

Erlina Burhan iD, Farchan Azzumar iD, Fira Alyssa Gabriella Sinuraya iD, Muhammad Ilham Dhiya Rakasiwi iD, Ihya Akbar iD, Farhan Mubarak iD, Anggit Tresna Rengganis iD, Rizky Abi Rachmadi iD, Hera Afidjati iD

JMIR Research Protocols · 2025

DOI: 10.2196/56519 ↗

At a glance

Studienprotokoll in JMIR Research Protocols, 2025. Written by Erlina Burhan and 8 co-authors. Institution: Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia-Persahabatan Hospital, Jakarta, Indonesia. Major MEDLINE topics: COVID-19, COVID-19 Vaccines, Vaccine Efficacy. 37 references. The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2 are the five common COVID-19 vaccines used in Jakarta. Randomized controlled trials have provided robust evidence of the safety and efficacy profile of these vaccines, but their real-world vaccine effectiveness against symptomatic COVID-19 and deaths in communities with social inequalities and health care constraints remains unclear.

Objective

This study aims to evaluate the real-world effectiveness of these COVID-19 vaccines during the waves associated with the Delta and Omicron variants by analyzing existing electronic health care sources.

Methods

A population-based study with a test-negative case-control design will be used to evaluate COVID-19 vaccine effectiveness in Jakarta, focusing on the Delta and Omicron waves. It includes adults 18 years and older who underwent reverse transcription polymerase chain reaction testing for symptomatic COVID-19, classifying them as cases or controls based on their test results. The analysis will consider multiple COVID-19 vaccines introduced during these periods, with participants categorized by vaccination status. Several potential confounders will be assessed, including demographic factors and comorbidities. Data will be linked from various health datasets, and statistical analyses will be performed to determine vaccine effectiveness and potential waning immunity over time. After data linkage, patients’ identities will be encrypted.

Results

The research, funded from 2022 to 2024, involved proposal preparation and ethical review in 2023 and enrollment from early 2024 to July 2024, resulting in about 4 million linked data points. Data analysis is ongoing, with initial results expected for publication in early 2025.

Conclusions

This study will be the first to evaluate the effectiveness of different types of COVID-19 vaccines (inactivated, viral-vector, and mRNA) used in Jakarta during the pandemic, providing valuable scientific evidence to inform future vaccination strategies in the country. International Registered Report Identifier (IRRID) DERR1-10.2196/56519

Subjects

MeSH terms (MEDLINE)

COVID-19COVID-19 VaccinesVaccine EfficacyHumansBNT162 VaccineSARS-CoV-22019-nCoV Vaccine mRNA-1273AdultCase-Control StudiesChAdOx1 nCoV-19Research DesignMaleFemaleMiddle AgedVaccines, Inactivated

Author keywords

COVID-19DeltaOmicronprotocolvaccinevaccine effectiveness

Substances

COVID-19 VaccinesBNT162 Vaccine2019-nCoV Vaccine mRNA-1273ChAdOx1 nCoV-19BIBP COVID-19 vaccinesinovac COVID-19 vaccineVaccines, Inactivated

Authors and institutions

  • Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia-Persahabatan Hospital, Jakarta, Indonesia.
  • Indonesian Society of Respirology, Jakarta, Indonesia.
  • Respiratory Programmatic Implementation and Research Institute, Jakarta, Indonesia.
  • Faculty of Public Health, Universitas Indonesia, Depok, Indonesia.

ORCID profiles: Erlina Burhan, Farchan Azzumar, Fira Alyssa Gabriella Sinuraya, Muhammad Ilham Dhiya Rakasiwi, Ihya Akbar, Farhan Mubarak, Anggit Tresna Rengganis, Rizky Abi Rachmadi, Hera Afidjati

Cite

APA

Burhan, E., Azzumar, F., Sinuraya, F. A. G., Rakasiwi, M. I. D., Akbar, I., Mubarak, F., Rengganis, A. T., Rachmadi, R. A., & Afidjati, H. (2025). Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data. JMIR Research Protocols. https://doi.org/10.2196/56519

Vancouver

Burhan E, Azzumar F, Sinuraya FAG, Rakasiwi MID, Akbar I, Mubarak F, et al. Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data. JMIR Research Protocols. 2025. doi:10.2196/56519

BibTeX
@article{Burhan2025,
  author = {Burhan, Erlina and Azzumar, Farchan and Sinuraya, Fira Alyssa Gabriella and Rakasiwi, Muhammad Ilham Dhiya and Akbar, Ihya and Mubarak, Farhan and Rengganis, Anggit Tresna and Rachmadi, Rizky Abi and Afidjati, Hera},
  title = {Real-World Effectiveness of COVID-19 Vaccines (ChAdOx-1s, CoronaVac, BBIBP-CorV, mRNA-1273, and BNT162b2) in Jakarta: Protocol for Test-Negative Design of Health Care Data},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/56519}
}
Start for free →